Search - tctmd.com

Displaying 161 - 180 of 183

Sort: Relevancy | Date

Presentation

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Presenter: Suresh R. Mulukutla

December 05, 2012

Presentation

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Presenter: S. Cassese

November 26, 2012

Presentation

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Presenter: Greg C. Flaker

October 09, 2012

Presentation

Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an ACS

Presenter: Andr?s Kom?csi

October 01, 2012

Presentation

RESET Trial: A New Strategy for Discontinuation of Dual Antiplatelet Therapy

Presenter: B-K Kim

September 19, 2012

Presentation

Double Antiplatelet Therapy After DES Implantation

Presenter: I. Ferreira-Gonz?lez

September 19, 2012

Presentation ESC 2012

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

Presenter: Willem Dewilde

August 28, 2012

Presentation ACVS 2012

Which Antiplatelets to Use for PCI?

Presenter: Dev Pahlajani

August 04, 2012

Presentation ACVS 2012

Peri-Operative Medical Management of Patient with Recurrent Ischemia

Presenter: Ravi Kumar Aluri

August 03, 2012

Presentation

Cilostazol Added to Aspirin and Clopidogrel Reduces Revascularization Without Increases in Major Adverse Events in Patients With DES

Presenter: Ryota Sakurai

July 12, 2012

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

Presentation

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Presenter: T. Tada

June 01, 2012

Presentation TCTAP 2012

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Presenter: Gregg W. Stone

April 26, 2012

Presentation GI2 2012

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Presenter: Fausto Feres

April 13, 2012

Presentation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Presenter: Marco Valgimigli

April 02, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Presentation

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Presenter: Hans-Christoph Diener

March 08, 2012

Presentation

Meta-Analysis of RCTs on Effect of Cilostazol on Restenosis and Outcomes After PCI

Presenter: S. Friedland

March 06, 2012

Presentation

Meta-Análisis of Ensayos Controlados Aleatorizaos sobre el Efecto del Cilostazol en la Re-estenosis y Resultados tras PCI

Presenter: S. Friedland

March 06, 2012

Advertisement

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an ACS

RESET Trial: A New Strategy for Discontinuation of Dual Antiplatelet Therapy

Double Antiplatelet Therapy After DES Implantation

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

Which Antiplatelets to Use for PCI?

Peri-Operative Medical Management of Patient with Recurrent Ischemia

Cilostazol Added to Aspirin and Clopidogrel Reduces Revascularization Without Increases in Major Adverse Events in Patients With DES

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Apixaban vs. Aspirin in Patients with A-fib and Previous Stroke or TIA

Meta-Analysis of RCTs on Effect of Cilostazol on Restenosis and Outcomes After PCI

Meta-Análisis of Ensayos Controlados Aleatorizaos sobre el Efecto del Cilostazol en la Re-estenosis y Resultados tras PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content